Leerink raised the firm’s price target on Encompass Health (EHC) to $130 from $120 and keeps an Outperform rating on the shares. The firm notes that Q1 results were incredibly strong underpinned by historical growth, favorable mix, tailwinds with de novos and strong expense controls. Leerink thinks Q1 results place Encompass Health on a current run-rate that already exceeds the high-end of its revised range.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health’s Earnings Call Highlights Growth and Challenges
- Encompass Health price target raised to $130 from $117 at UBS
- Encompass Health price target raised to $135 from $116 at Truist
- Encompass Health price target raised to $125 from $110 at RBC Capital
- Encompass Health price target raised to $130 from $120 at Raymond James